Bristol-Myers Squibb BMY Sotyktu — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's sotyktu — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's sotyktu — total revenues?
- Bristol-Myers Squibb (BMY) reported sotyktu — total revenues of $87M in Q2 2026.
- How has Bristol-Myers Squibb's sotyktu — total revenues changed year-over-year?
- Bristol-Myers Squibb's sotyktu — total revenues increased by 24.3% year-over-year, from $70M to $87M.
- What is the long-term trend for Bristol-Myers Squibb's sotyktu — total revenues?
- Over 3 years (2022 to 2025), Bristol-Myers Squibb's sotyktu — total revenues has grown at a 231.0% compound annual growth rate (CAGR), from $8M to $290M.
- What does sotyktu — total revenues mean?
- This metric represents the total global net sales generated from the commercialization of Sotyktu, a selective tyrosine kinase 2 (TYK2) inhibitor. It serves as a key indicator of the product's market adoption and competitive positioning within the immunology and dermatology therapeutic landscape. Monitoring this revenue stream is essential for assessing the company's growth trajectory in non-oncology specialty markets.